Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$53.83
▼ $0.45 (-0.8%)
Market data updated: 09/19 11:29 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
$2.78B
Day Range
$53.12 - $54.46
52-Week Range
$13.95 - $55.16
Beta
—
Next Earnings
02.11.2026
Support
$27.68
Resistance
$55.16
CDNA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+264.5% (1Y)
Strengths: 12/26 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Operating margin stability
Operating margin is stable or improving over time
Quality
Biggest negative driver
Operating margin
Operating margin: -8.1% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
56
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
3d ago · $52.37
Evidence: Euphoria score crossed 55 (now 56)
What happened after
Still awaiting outcome
11d ago · $50.88
Evidence: Euphoria score crossed 55 (now 59)
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
43
Quality
58
Value
50
Momentum
70
Risk
48
Sentiment
100
Fundamental
30
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **CareDx, Inc.** has centered on its strong financial momentum and investor optimism. Analysts, including Canaccord Genuity, have initiated coverage with a **Buy rating and a $65 price target**, while financial screens highlight its **rapid earnings growth (117% EPS), zero debt, and robust technical performance**. The company’s stock has surged—with **124.7% gains over three months and a 3.8x year-to-date return**—positioning it as a resilient player in digital health amid workforce challenges.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about CareDx, Inc.. News trend score: 100. Reason: 15 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
56
🎯 Conviction (vs. Emotion)
40
Psychology
64
Fundamentals
30
Technical
70
Valuation
50
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+106%
Market Narrative
76
Fundamental Reality
40
Narrative Gap
+36
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for CDNA strongly suggests a dominant euphoric state, where extreme positive sentiment and detached momentum from fundamentals drive participation. The narrative gap (75 vs. 40) further implies investors are overestimating growth potential relative to reality. Overconfidence and FOMO reinforce this, as traders prioritize short-term gains over valuation or fundamentals. The key open question is whether this disconnect can persist amid peer underperformance, which may signal a potential shift in relative valuation dynamics.
Updated: 09/09/2026, 03:23 AM
What could change this?
👥 What the crowd believes
"Canaccord Genuity analyst Kyle Mikson initiates coverage on CareDx with a Buy rating and announces Price Target of $65."
"CareDx passes Louis Navellier's 8 growth rules: strong earnings revisions, sales growth, margins, cash flow, ROE."
"CareDx has shown building momentum, with a 30.9% 1-month share price return and 124.7% 3-month return."
"CareDx is positioned for growth as digital health expands and workforce shortages reshape medical services."
🧠 Market Brain events driving this
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 96/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
The stark divide in verdicts for CDNA reflects deep methodological differences in how these investors evaluate stocks. Walter Bagehot’s near-perfect score highlights his focus on liquidity and resilience during crises, suggesting the stock’s financial health would weather a downturn—something most others overlook. Meanwhile, the majority of methodologies, from Graham’s defensive criteria to Lynch’s growth-at-a-reasonable-price rule, dismiss it as either overvalued, lacking growth potential, or too volatile, with scores clustering in the mid-to-low 40s. Howard Marks and Charles Mackay’s low scores flag it as late-cycle or speculative, while Morgan Housel’s zero score underscores its volatility as a red flag for patient, long-term investors. The contrast between Bagehot’s liquidity-first approach and the cautionary signals from cycle analysts like Marks and Mackay reveals whether the stock’s strength lies in its stability or its perceived risk.
Walter Bagehot
Lombard Street (1873)
🟢 96
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 65
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 53
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 49
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 47
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 47
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 44
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 43
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 43
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 35
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 25
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🔴 22
Risk/valuation combination Marks would flag as a caution sign
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 21
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 17
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 3
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (8 bullish · 4 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-8.1%
Net Margin
-5.6%
EBITDA Margin
-4.2%
ROE
-7.0%
ROA
-5.2%
ROIC
—
EPS
-$0.40
Cash
$65.43M
Total Debt
—
Current Ratio
2.86
Debt/Equity
—
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$5.69
Tangible Book Value per Share (Tangible NAV)
$4.33
Sentiment based on basic keywords (not AI) — 15 positive, 5 neutral, 0 negative out of the last 20 articles.
ChartMill · 19.9.2026
Yahoo · 14.9.2026
ChartMill · 10.9.2026
Yahoo · 9.9.2026
Zacks · 9.9.2026
Yahoo · 8.9.2026
Zacks · 8.9.2026
ChartMill · 5.9.2026
Benzinga · 2.9.2026
MT Newswires · 2.9.2026
ChartMill · 28.8.2026
Yahoo · 27.8.2026
Zacks · 27.8.2026
Yahoo · 25.8.2026
Zacks · 25.8.2026
ChartMill · 25.8.2026
Yahoo · 24.8.2026
Zacks · 24.8.2026
Yahoo · 23.8.2026
Simply Wall St. · 23.8.2026
CareDx, Inc. (CDNA) currently has a StockIQ AI score of 56/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
CDNA currently scores 56/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
CDNA's technical score is 70/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Operating margin is stable or improving over time; Current ratio: 2.86; Price is above the 50-day average.
Based on the real signals StockIQ computed: Operating margin: -8.1% (negative); Net margin: -5.6% (negative); ATR: 4.0% of price.
StockIQ has no recorded dividend payment history for CDNA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 14 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Bickerstaff George | Open Market Sale | 5.8.2026 | 20,000 | -20,000 | $46.29 |
| Novack Jeffrey Adam | Open Market Sale | 5.8.2026 | 2,188 | -2,188 | $46.15 |
| Novack Jeffrey Adam | Open Market Sale | 5.8.2026 | 500 | -500 | $46.75 |
| Bickerstaff George | Open Market Sale | 5.8.2026 | 134,061 | -20,000 | $46.29 |
| Novack Jeffrey Adam | Open Market Sale | 5.8.2026 | 106,575 | -2,188 | $46.15 |
| Novack Jeffrey Adam | Open Market Sale | 5.8.2026 | 106,075 | -500 | $46.75 |
| COURNOYER CHRISTINE | Open Market Sale | 4.8.2026 | 16,000 | -16,000 | $46.94 |
| Goldberg Michael | Open Market Sale | 4.8.2026 | 44,700 | -44,700 | $47.06 |
| COURNOYER CHRISTINE | Open Market Sale | 4.8.2026 | 42,943 | -16,000 | $46.94 |
| Goldberg Michael | Open Market Sale | 4.8.2026 | 61,738 | -44,700 | $47.06 |
| Novack Jeffrey Adam | Tax Withholding in Shares | 1.8.2026 | 2,872 | -2,872 | $47.85 |
| Novack Jeffrey Adam | Tax Withholding in Shares | 1.8.2026 | 108,763 | -2,872 | $47.85 |
| Valantine Hannah | Open Market Sale | 16.7.2026 | 100 | -100 | $36.55 |
| Valantine Hannah | Exercise of Derivative Securities | 16.7.2026 | 7,606 | -7,606 | — |
| Hanna John Walter JR | Open Market Sale | 16.7.2026 | 68,000 | -68,000 | $39.01 |
| Hanna John Walter JR | Exercise of Derivative Securities | 16.7.2026 | 118,000 | -118,000 | — |
| Valantine Hannah | Exercise of Derivative Securities | 16.7.2026 | 16,048 | +16,048 | $14.19 |
| Hanna John Walter JR | Open Market Sale | 16.7.2026 | 50,000 | -50,000 | $36.11 |
| Valantine Hannah | Open Market Sale | 16.7.2026 | 28,679 | -28,679 | $36.14 |
| Hanna John Walter JR | Exercise of Derivative Securities | 16.7.2026 | 118,000 | +118,000 | $8.20 |
| Valantine Hannah | Exercise of Derivative Securities | 16.7.2026 | 5,125 | -5,125 | — |
| Valantine Hannah | Exercise of Derivative Securities | 16.7.2026 | 16,048 | -16,048 | — |
| Valantine Hannah | Exercise of Derivative Securities | 16.7.2026 | 5,125 | +5,125 | $7.96 |
| Valantine Hannah | Exercise of Derivative Securities | 16.7.2026 | 7,606 | +7,606 | $20.56 |
| Hanna John Walter JR | Exercise of Derivative Securities | 16.7.2026 | 771,448 | +118,000 | $8.20 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,828,536 shares short as of 2026-08-31 · vs. 6,135,225 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
55.9% of trading volume this week was short selling, vs. 54.9% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology